NantKwest and ImmunityBio’s hAd5-Covid-19 is a novel Covid-19 vaccine candidate designed to target the inner nucleocapsid (N) and the outer spike (S) protein, as well as activate both The post ImmunityBio, NantKwest dose first patient in novel Covid-19 vaccine candidate trial appeared first on Pharmaceutical Business review. … [Read more...]

Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi in Switzerland. Alkindi is the first preparation of hydrocortisone specifically designed The post EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi appeared first on Pharmaceutical Business review. … [Read more...]

Branaplam has been demonstrated to decrease levels of mutant huntingtin protein in preclinical models, said Novartis. Based on the results, Novartis aims to begin a development programme for The post Novartis gets FDA orphan drug status for branaplam to treat Huntington’s disease appeared first on Pharmaceutical Business review. … [Read more...]

These data presented at IDWeek 2020 show that switching from a standard regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent to Biktarvy is an The post Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans appeared first on Pharmaceutical Business review. … [Read more...]